Abstract: An engine system includes an internal combustion engine having an intake duct and an exhaust duct; a flow control module fluidly coupled to the intake duct; a compressor in fluid communication with the intake duct via the flow control module; a heat exchanger having an exhaust flow path in fluid communication with the exhaust duct, and having an oxidizer flow path, an outlet of the compressor being in selective fluid communication with the intake duct via the flow control module and the oxidizer flow path of the heat exchanger; a first temperature sensor in fluid communication with the intake duct; and a controller operatively coupled to the flow control module and the first temperature sensor, the controller being configured to actuate the flow control module between a first configuration and a second configuration based at least in part on a signal from the first temperature sensor.

Abstract: An engine system includes an internal combustion engine having an intake duct and an exhaust duct; a flow control module fluidly coupled to the intake duct; a compressor in fluid communication with the intake duct via the flow control module; a heat exchanger having an exhaust flow path in fluid communication with the exhaust duct, and having an oxidizer flow path, an outlet of the compressor being in selective fluid communication with the intake duct via the flow control module and the oxidizer flow path of the heat exchanger; a first temperature sensor in fluid communication with the intake duct; and a controller operatively coupled to the flow control module and the first temperature sensor, the controller being configured to actuate the flow control module between a first configuration and a second configuration based at least in part on a signal from the first temperature sensor.

Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

Abstract: Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.

Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.